Latest Breaking News On - Expansion study expected - Page 1 : comparemela.com

NXP800 Phase 1a Dose-Escalation Study Progressing as Planned, Commencement of Phase 1b Expansion Study Expected in Q1 2023NXP800 IND Cleared by the U.S. FDA, U.S. and U.K. Sites Now Participating in. | August 5, 2022

United kingdomUnited statesChristopherm calabreseRon bentsurCompany contactDrug administrationExchange commissionAmerican association for cancer researchEuropean society for paediatric oncologyClinical programNuvectis pharma incBrain tumor groupGlobenewswire incDose escalation study progressingExpansion study expectedNow participating